River Global Investors LLP Sells 163,521 Shares of Kenvue Inc. (NYSE:KVUE)

River Global Investors LLP cut its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 73.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 60,049 shares of the company's stock after selling 163,521 shares during the period. River Global Investors LLP's holdings in Kenvue were worth $1,293,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Clearstead Advisors LLC purchased a new stake in shares of Kenvue in the third quarter valued at about $25,000. Planned Solutions Inc. bought a new position in shares of Kenvue during the 4th quarter worth approximately $27,000. Venturi Wealth Management LLC purchased a new position in shares of Kenvue in the 3rd quarter worth approximately $28,000. EverSource Wealth Advisors LLC purchased a new position in shares of Kenvue in the 3rd quarter worth approximately $28,000. Finally, Cullen Frost Bankers Inc. bought a new position in shares of Kenvue in the third quarter valued at approximately $29,000. Institutional investors and hedge funds own 97.64% of the company's stock.

Analyst Ratings Changes

Several research analysts have weighed in on KVUE shares. William Blair began coverage on Kenvue in a research report on Wednesday, April 3rd. They issued a "market perform" rating on the stock. Sanford C. Bernstein assumed coverage on shares of Kenvue in a report on Thursday, April 11th. They set an "underperform" rating and a $18.00 price objective for the company. Royal Bank of Canada dropped their target price on shares of Kenvue from $25.00 to $24.00 and set an "outperform" rating on the stock in a research note on Friday, February 9th. JPMorgan Chase & Co. reduced their target price on shares of Kenvue from $25.00 to $24.00 and set an "overweight" rating for the company in a research report on Friday, February 9th. Finally, The Goldman Sachs Group assumed coverage on shares of Kenvue in a report on Friday, March 1st. They issued a "neutral" rating and a $20.00 price target on the stock. One analyst has rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $24.85.

Kenvue Trading Up 0.4 %

KVUE stock traded up $0.08 during mid-day trading on Friday, reaching $19.20. 15,941,057 shares of the company traded hands, compared to its average volume of 15,351,688. The company has a fifty day moving average price of $19.82 and a 200-day moving average price of $20.12. Kenvue Inc. has a 52-week low of $17.82 and a 52-week high of $27.80. The company has a quick ratio of 0.78, a current ratio of 1.12 and a debt-to-equity ratio of 0.69.

Kenvue (NYSE:KVUE - Get Free Report) last posted its earnings results on Thursday, February 8th. The company reported $0.31 earnings per share for the quarter, topping analysts' consensus estimates of $0.28 by $0.03. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The business had revenue of $3.67 billion for the quarter, compared to analyst estimates of $3.78 billion. The business's revenue for the quarter was down 2.7% compared to the same quarter last year. On average, analysts anticipate that Kenvue Inc. will post 1.15 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 22nd. Investors of record on Wednesday, May 8th will be paid a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 4.17%. The ex-dividend date is Tuesday, May 7th.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.